Emerging Treatment Options for BRAF-mutant Colorectal Cancer
[Gastrointestinal Cancer: Targets and Therapy] This review presents the most up-to-date molecular, clinical, and therapeutic data, including an overview of a current phase 3 study assessing the efficacy of simultaneous BRAF, EGFR, and MEK inhibition among patients with BRAFV600E-mutant CRC.
